Home > Boards > US Listed > Biotechs >

ChemoCentryx (CCXI)

Add CCXI Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/5/2020 9:04:14 PM - Followers: 20 - Board type: Free - Posts Today: 0

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation.

Board of Directors

Thomas J. Schall, Ph.D.President, Chief Executive Officer and Chairman of the Board
Dr. Schall is the founder of our company and has served as our President, Chief Executive Officer and Director since we commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall’s laboratories have been responsible for the discovery or co-discovery of a large percentage of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

Thomas A. EdwardsRetired Partner, Latham & Watkins, LLP
Thomas A. Edwards has served on our board of directors since July 2015. Until his retirement in March 2014, Mr. Edwards practiced law with Latham & Watkins LLP, an international law firm, since 1983, having become partner in January 1991. His practice focused on general corporate and securities law, including capital financings, acquisitions, divestitures and spin-offs of companies and partnerships. Mr. Edwards earned his bachelor’s degree from Harvard College and his law degree from Harvard Law School.

Joseph M. Feczko, M.D.Former Senior Vice President and Chief Medical Officer, Pfizer Inc.
Dr. Feczko has served on our board of directors since April 2012. Until his retirement in May 2009, Dr. Feczko was Senior Vice President and Chief Medical Officer of Pfizer Inc. and a member of its Executive Leadership Team with global responsibilities for all aspects of the company’s medical, regulatory and safety activities. Dr. Feczko served Pfizer in both New York and the United Kingdom since 1982, where he held positions of increasing responsibility in clinical research and regulatory affairs and safety, culminating in the role of Chief Medical Officer. Dr. Feczko is board-certified in Internal Medicine and Infectious Diseases. He has a B.S. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine. Dr. Feczko also serves on the board of directors of Keryx Biopharmaceuticals, Inc. and Cytheris, SA. Dr. Feczko also serves as chairman of the board of directors of Cardoz Pharmaceuticals AB (Stockholm, Sweden) and as a member of the Supervisory Board of uniQure B.V., based in the Netherlands.

Roger C. Lucas, Ph.D.Vice Chairman, Bio-Techne Corporation
Dr. Lucas has served on our board of directors since September 1997. Since 1995, Dr. Lucas has served as Vice Chairman and a member of the board of directors of Bio-Techne, formerly Techne Corporation, a biotechnology company. From 1985 to 1995, Dr. Lucas served as the Chief Scientific Officer, Senior Executive Vice President and Secretary of Bio-Techne Corporation and the founder of its Biotechnology Division. Prior to this, Dr. Lucas was Vice President of Research at R&D Systems, now a subsidiary of Bio-Techne, where he worked for over ten years. Dr. Lucas received his B.S. in biology and chemistry from St. Mary’s College, Minnesota and his Ph.D. in physiology and cell biology from Illinois Institute of Technology. Dr. Lucas also presently serves on the board of directors of a number of privately held companies.

Geoffrey M. ParkerFormer Executive Vice President and Chief Financial Officer, Anacor Pharmaceuticals, Inc.
Mr. Parker has served on our board of directors since December 2009. From September 2010 to May 2015, Mr. Parker was Chief Financial Officer of Anacor Pharmaceuticals, Inc. after serving in a consulting capacity since December 2009. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, Inc. a biotechnology company and previously served as Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. From 1997 to 2009, Mr. Parker directed Goldman Sachs’ West Region Healthcare Investment Banking practice. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm. Mr. Parker received his A.B. in Engineering Sciences and Economics from Dartmouth College and his M.B.A. from Stanford University.

James L. TyreeFormer Executive Vice President, Abbott Laboratories
Mr. Tyree has served on our board of directors since June 2012. Mr. Tyree is the co-founder and managing partner of Tyree & D’Angelo Partners, a private equity investment firm. During the last fifteen years, Mr. Tyree has held numerous executive positions at Abbott Laboratories, including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition and Executive Vice President Global Pharmaceuticals. He retired as President of Abbott Biotechnology Ventures in March 2012. Prior to joining Abbott, Mr. Tyree was the President of SUGEN, Inc., a biotechnology company focused on oncology. Earlier in his career, Mr. Tyree held management positions in Bristol-Myers Squibb, Pfizer and Abbott. Over his entire career, he was a four-time expatriate living and working over six years in Latin America and seven years in Japan. Mr. Tyree is a member of the Advisory Board of the University of Chicago Booth Graduate School of Business, a member of the Chicago Council on Global Affairs and co-chairman of the Global Health Policy Roundtable. Mr. Tyree also serves as a director for a number of privately held companies. Mr. Tyree earned Bachelor’s Degrees in Psychology and Forensic Studies and a Master’s Degree in Business Administration from Indiana University.

Shares outstanding 44.073.659 a/o Aug 2015
Authorized shares 200.000.000
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CCXI News: ChemoCentryx to Present at Two Upcoming Investor Conferences 02/25/2021 08:30:00 AM
CCXI News: Initial Statement of Beneficial Ownership (3) 02/24/2021 12:13:41 PM
CCXI News: ChemoCentryx names new EVP & COO 02/24/2021 09:11:28 AM
CCXI News: ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer 02/24/2021 08:30:00 AM
CCXI News: ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021 02/23/2021 08:30:00 AM
#205   Exited position today, was looking for a quick Cosa 10/05/20 09:04:14 PM
#204   They just posted a beat on revenues today. Cosa 08/10/20 08:04:33 PM
#203   It's holding and I think more is coming... catchmeifyoucan 12/09/19 07:49:37 PM
#202   This is next..... ALT, just a passing remark catchmeifyoucan 12/04/19 07:44:37 PM
#201   Getting nervous could drop today damondon 11/29/19 06:50:23 AM
#200   * * $CCXI Video Chart 11-26-2019 * * ClayTrader 11/26/19 04:39:19 PM
#199   CCXI did it. Once of my many biotech's cjstocksup 11/26/19 10:32:57 AM
#198   I sold half after hours in case if Glider549 11/26/19 09:46:29 AM
#197   PT raised to $56 vs. $17 at crudeoil24 11/26/19 09:15:11 AM
#196   CCXI up 325% @ 34.32 > VFMCRP and crudeoil24 11/26/19 09:12:54 AM
#195   Congrats to all those that stuck with CCXI Whalatane 11/26/19 08:40:21 AM
#194   Alerted entry at $8, only thing they were Zmill 11/25/19 11:29:43 PM
#193   YEEEHAWWW!!!! The company announces positive topline data from its pivotal Glider549 11/25/19 04:52:33 PM
#192   Wow - RUnning hard here AH - TaxiCaT 11/25/19 04:41:12 PM
#191   * * $CCXI Video Chart 06-05-2019 * * ClayTrader 06/05/19 04:17:56 PM
#190   Read this!!! Is soooo goooood Diamonds are forever!!! https://m.facebook.com/v Chorizon 03/26/19 03:36:47 AM
#189   * * $CCXI Video Chart 09-29-18 * * ClayTrader 09/29/18 05:58:40 PM
#188   CCXI has found great support since March. More REDEMPTIVE 06/08/17 10:42:37 AM
#187   Some more great news today. This is going REDEMPTIVE 03/22/17 09:41:15 AM
#186   Great news and moving up sharply:https://globenewswire.com/news-release/2016/12/ REDEMPTIVE 12/22/16 01:24:24 PM
#185   Hey Future energy, great posts and DD thanks, REDEMPTIVE 11/11/16 08:42:51 PM
#184   wauw such an amazing days with 8$ a FutureEnergy 11/11/16 05:09:27 PM
#183   premarket bid 6.95... lets welcome the 7's again! FutureEnergy 11/09/16 08:43:37 AM
#182   Take @ look at this year great news FutureEnergy 10/20/16 10:57:07 AM
#181   ChemoCentryx Appoints Henry A. McKinnell, Jr. to Board FutureEnergy 10/20/16 10:42:22 AM
#180   October 17 FDA awards 21 grants to stimulate FutureEnergy 10/18/16 12:39:24 PM
#179   More good news..ChemoCentryx’s CCR2 Inhibitor CCX872 Shown to FutureEnergy 10/18/16 12:35:27 PM
#178   bid 6.12 and climbing! FutureEnergy 10/18/16 09:34:41 AM
#177   FDA 500.000 $ granted! + major news yesterday goooooooooo FutureEnergy 10/18/16 09:33:08 AM
#176   get ready for a big ride today!!! FutureEnergy 10/18/16 09:30:04 AM
#175   ChemoCentryx Announces Presentation of Positive Data from Ongoing FutureEnergy 10/17/16 12:03:48 PM
#174   Hi Redemptive. FutureEnergy 10/06/16 07:06:14 PM
#173   let's prepare for a big shake @ the FutureEnergy 10/05/16 03:35:28 PM
#172   Believe they have a P 2 trial thats Whalatane 09/30/16 03:08:42 PM
#171   Glad I held may shares. REDEMPTIVE 09/30/16 02:13:24 PM
#170   Welcome 6's !!! Have a Nice ride to FutureEnergy 09/30/16 01:47:13 PM
#169   6 here we come!! FutureEnergy 09/27/16 10:26:09 AM
#168   5.8 new high! (6 month) FutureEnergy 09/27/16 10:23:49 AM
#167   5.55 ! and over 100000 volume... here we gooooooooo FutureEnergy 09/27/16 10:07:05 AM
#166   Nice to see we are going back to FutureEnergy 09/27/16 09:52:27 AM
#165   Confidential Treatment Order (ct Order) FutureEnergy 09/22/16 10:45:45 AM
#164   Must read.... I was surprised about the Friday FutureEnergy 09/06/16 10:30:09 AM
#163   welcome back 5's :-) still nothing if you FutureEnergy 08/31/16 09:12:12 AM
#162   Slow but steady back to $ 5... FutureEnergy 08/25/16 10:26:26 AM
#161   Any insight on what's going on here since REDEMPTIVE 08/09/16 03:15:22 PM
#160   New news will come out in the next FutureEnergy 07/28/16 03:04:43 PM
#159   Company needs to get some news out on REDEMPTIVE 07/25/16 02:25:07 PM
#158   Ron yes , well I still have Whalatane 07/16/16 10:42:54 AM
#157   Anyone still here? ronpopeil 07/15/16 01:41:33 PM
#156   Bought in yesterday. CCXI getting hit because biotech ronpopeil 07/14/16 11:02:53 AM
Consent Preferences